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and Jamie A. Davies
IUPHAR/BPS Guide to PHARMACOLOGY, Centre for Discovery Brain Sciences, Deanery of Biomedical Sciences, University of
Edinburgh EH8 9XD, Edinburgh, U.K.
ABSTRACT: Connecting chemistry to pharmacology has
been an objective of Guide to PHARMACOLOGY (GtoPdb)
and its precursor the International Union of Basic and Clinical
Pharmacology Database (IUPHAR-DB) since 2003. This has
been achieved by populating our database with expert-curated
relationships between documents, assays, quantitative results,
chemical structures, their locations within the documents, and
the protein targets in the assays (D-A-R-C-P). A wide range of
challenges associated with this are described in this
perspective, using illustrative examples from GtoPdb entries.
Our selection process begins with judgments of pharmaco-
logical relevance and scientific quality. Even though we have a
stringent focus for our small-data extraction, we note that assessing the quality of papers has become more difficult over the last
15 years. We discuss ambiguity issues with the resolution of authors’ descriptions of A-R-C-P entities to standardized identifiers.
We also describe developments that have made this somewhat easier over the same period both in the publication ecosystem
and recent enhancements of our internal processes. This perspective concludes with a look at challenges for the future, including
the wider capture of mechanistic nuances and possible impacts of text mining on automated entity extraction.
1. INTRODUCTION
Connecting chemistry to pharmacology (c2p) can be under-
stood intuitively as the effects of exogenous substances on the
systems of living organisms, generally associated with exploring a
human therapeutic application. However, it is necessary to limit
our coverage of this extensive topic in this perspective. First, as
implied from the title, this will focus on the c2p subset
encompassed in the International Union of Basic and Clinical
Pharmacology/British Pharmacological Society (IUPHAR/
BPS) Guide to PHARMACOLOGY (GtoPdb, http://www.
guidetopharmacology.org). This includes the addition of the
new IUPHAR Guide to IMMUNOPHARMACOLOGY
(http://www.guidetoimmunopharmacology.org). Second, it
will concern mostly small molecules but also extends to
moderate-size peptides and therapeutic nucleotides. Third,
while it is not the only provenance option, we will restrict
ourselves to scientific publications for the primary reports of
pharmacology. Fourth, the focus is on effects that can be
plausibly explained based on experimental results as a molecular
mechanism of action (mmoa). The area to cover thus becomes
more circumscribed as approximating to the document corpus
covering pharmacology (i.e., largely journal papers and patents).
We will also cover aspects of drug discovery and chemical
biology, since these domains are not usefully separable from
pharmacology. The same argument applies to metabolomics,
but we leave this domain mainly to other resources such as the
Human Metabolome Database.1
GtoPdb is a moderate-scale knowledgebase of c2p relation-
ships, curated manually since 2003 from the pharmacological
literature. Detailed content statistics and feature descriptions are
available in our Nucleic Acids Research (NAR) Database issue
article2 and via our website and blog. GtoPdb has accumulated a
matrix of 1700 targets and 15 500 activity values for 7000
ligands, guided by expert members of the IUPHAR Committee
on Receptor Nomenclature and Drug Classification (NC-
IUPHAR) and its 96 subcommittees. This de facto “super-
curator network” encompasses over 500 individual scientists
(http://www.guidetopharmacology.org/nciuphar.jsp).
Our aim is to provide quantitative data on compounds
suitable to use in the laboratory as recommended by experts.
Consequently, GtoPdb has a high level of selectivity (including
being mainly focused on human data). Our quality selection
criteria were described for our first publication back in 2009.3
We use several indicators to demonstrate the value impact of this
approach across our broad user community. These include our
user counts (via Google Analytics) of 19 000 per month from
200 countries, web services accesses, data downloads, good
citation rates for all six of our NAR Database issue papers, cross-
linking from over 20 other sources, and our 2016 inclusion in the
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ELIXIR UK Node resources for Human Health and Disease
(http://www.elixiruknode.org/human-health-and-disease/).
2. DESCRIBING CHEMISTRY TO PHARMACOLOGY
(C2P) CONNECTIONS
2.1. D-A-R-C-P Concept.We can conceptualize c2p as core
relationships (i.e., chain of links) between a document, an assay,
its quantitative result, a chemical structure, and a protein target.4
A useful shorthand for this is D-A-R-C-P (note the order is not
crucial but will be adhered to here for simplicity). A topical
example is illustrated in Figure 1.
In this case “C”, as BIA 10-2474, is the code number of the
BIAL Portugal, Phase I compound that caused a fatality during a
French clinical trial in January 2016.5 The following c2p
relationships can be extracted:
• “D” is a 2017 paper entitled “Activity-based protein
profiling reveals off-target proteins of the FAAH inhibitor
BIA 10-2474” (although not from BIAL). Thus, “D” can
be specified as PMID 28596366, or by its DOI: 10.1126/
science.aaf7497.
• From this document, we can extract “A” as an IC50
measurement on purified protein in vitro, which records
a (low) potency result “R” of 7500 nM. R can also be
expressed as 7.5 μM or a pIC50 of 5.12.
• We can specify “C” by an IUPAC name N-cyclohexyl-N-
methyl-4-(1-oxidopyridin-1-ium-3-yl)imidazole-1-car-
boxamide. Alternatively, we could use the PubChem
Compound ID CID 66554294,5 the GtoPdb Ligand ID
(LID) 9001, or an InChIKey DWCWWJONKWHPDD-
UHFFFAOYSA-N (full InChI strings or SMILES can also
be used).
• The entity “P” could use the HGNC-approved gene name
for the enzyme,6 as “fatty acid amide hydrolase”, its
symbol, FAAH, or the Swiss-Prot human protein
accession O00519.
While such D-A-R-C-P mappings may seem highly specific,
there are other useful relationships that can be extracted. For
example, while the publication is “about” BIA 10-2474 and the
inhibition of the FAAH enzyme, it also includes the putative off-
targets and extrapolates to the paralogue FAAH2 (by
homology). We can also determine that CID 66554294 has
1199 nearest neighbors by chemical similarity within PubChem,
thereby inferring that FAAH inhibitors are (or at least have
been) an active area of research. Typically, in structure−activity
relationship (SAR) papers, there are multiple “R-C”s for the
same “D-A” and P. Thus, within PMID 28596366, we can
identify two additional C’s as the metabolite BIA 10-2639 (CID
66554294) and a reference inhibitor PF-04457845 (CID
24771824), where R is 4100 and 10 nM, respectively.
Figure 2 illustrates additional c2p inferences from powerful
features of the PubMed/NCBI Entrez system.7 From the
available “D-D” links, we can find useful further references,
including a primary reference for the first declaration of in vitro
activity measurements against PF-04457845.
2.2. c2p Curation in GtoPdb. GtoPdb utilizes expert
curation to identify, extract, and convert unstructured knowl-
edge from the published article (as text, chemical images and
result tables) into structured database entries. This can be
illustrated for the example above by looking at the table of
entries GtoPdb has selected for FAAH inhibitors shown in
Figure 3.
This includes the three D-A-R-C-Ps already mentioned for
BIA 10-2474, BIA 10-2639, and PF-04457845, with the latter
having two Dʼs and two Rʼs indicated as a range. In the FAAH
table, we have 15 unique Cʼs (as ligands), 23 Rʼs (as affinities),
and 13 Dʼs (as references). We also have four instances of rat
data. In these cases, D-A will be the same, R values will be
different, and P will be P97612 for the rat enzyme. If we inspect
the analogous records for human FAAH2 (i.e., where P =
Q6GMR7, GtoPdb TID 1401), we can find inhibition data for
four of the compounds. Importantly, in this case, there is no
rodent orthologue for FAAH2.
Over the years, we have extended our data model to support
additional relationships. One of these was a sixth attribute in the
Figure 1. Example of a D-A-R-C-P relationship chain. Taken from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=
9001.
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link, “L”, as a reference to the explicit location(s) of C within the
document D. Our shorthand was thus extended to D-A-R-C-L-
P. The utility is that from a series of compounds specified in a
typical medicinal chemistry paper, we specify the intradocument
named leads, most often as listed compound names from an
analogue series and/or the code number of the declared lead
compound. Users can thus quickly see both what the paper is
about and how C has been provenanced in terms of curatorial
choice. This innovation was helpful as we began to include
patents as Dʼs (which often extend into 100s of IC50s), as a
consequence of expanded patent-extraction content in Pub-
Chem.5 An example from Figure 3 is ligand ID 9077, showing
the location as “example 13 [WO2009109743]” (i.e., example
13 is L for its exact location in the document), which was
selected as a representative potent inhibitor from a patent filed
by the company Vernalis.
We informally refer to the citations we associate with our
ligands as primary, secondary, or tertiary publications. “Primary
citation” has already been described above as A-R-C-L-P where
the data are obtained with purified protein in vitro. We use the
term “secondary citation”, where the publication D is about in
vivo testing in animal models and typically cites back to a
primary paper. “Tertiary citation” is applied to clinical reports
that typically cite both primary and secondary studies. These
divisions are somewhat arbitrary and not without limitations,
but in practice, we find that this classification offers users a small
set of core linked references, anchored to the same “C-P”, as
starting points for data mining and further exploration of the
literature.
Another important aspect of citations associated with our
curated references for ligands is the dissemination of these in
PubChem. GtoPdb has been a submitter to PubChem since
2008, but in the last few years, as a consequence of the reference
curation expansion described above, we are now one of the
major expert annotation sources of “C-D” (see Table 1 in ref 5).
In addition, essentially via the processes above, we are also one
of the most stringent in terms of key compounds. All of these are
in D-A-R-C-P chains and many are full D-A-R-C-L-P. The
statistics are shown in Table 1.
3. CHALLENGES OF c2p CURATION
One of the challenges for GtoPdb is to cover c2p with modest
biocurator resources, supported by the work of NC-IUPHAR
subcommittees. We address this by exercising judgment on what
to include and, equally importantly, what to leave out. We also
may not pick up early development leads or even new phase 1
Figure 2. Relationships within the Entrez system available as links from the right-hand facets of a PubMed entry. “Similar articles” is essentially a
heuristic clustering of “aboutness”, while “cited by” provides forward connectivity within the same knowledge domain. “Related information” links to
NCBI database cross-references including PubChem Substance (SID), Compound (CID), and BioAssay, MeSH keyword matches, and protein
structures in the Protein Data Bank (PDB). In this case, the three “PubChem substance” links have entered the system via the PubChem submissions
from GtoPdb (see section below on PubChem links). The “MeSH keyword” look-up brings back three CIDs for BIA 10-2474, PF-04457845, and the
less relevant urea (n.b. MeSH annotators did not select the metabolite BIA 10-2639 as a keyword but could do if this becomes a main theme of a future
paper).
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compounds for popular targets toward the top end of our ligand
distribution (e.g., the dopamine D2 receptor TID 215 with 105
ligands in the download list). However, we try to capture all
approved drugs and phase III candidates. As further examples of
selectivity judgments, our BACE1 entry (TID 2330) has 21
inhibitors listed compared to 8545 for the ChEMBL (release 24)
entry. For another historically popular target, F2 (thrombin),
the GtoPdb/ChEMBL mapped compounds ratio is 10:8264.
However, since we are not constrained by coverage mandates,
we can introduce committee-recommended positive biases.
Examples here include the recent crop of G-protein-coupled
receptor (GPCR)-biased agonists and allosteric modulators,
where we have curated those with PDB structures of ligand
binding pockets. In addition, we have introduced a new tool,
SynPharm, to allow synthetic biologists to exploit PDB ligand
binding sequences.8 We also use our judgment in the opposite
direction (i.e., lowering the bar) in that we pick up low-potency
compounds directed against novel targets or orphan GPCRs
while maintaining a potency cutoff of ∼10 μM. This is because
these papers represent new pharmacological starting points and
thus extend the druggable proteome coverage. More potent
compounds may eventually be curated against the same target,
but we generally do not purge data-supported first-generation
ligands.
A second crucial challenge for c2p is to ensure (as far as
possible) that the reported experimental results we choose to
curate are correct. This has become harder as GtoPdb domain
coverage expands into new areas (especially enzymes and other
nonreceptor or channel proteins, which were our original focus
prior to 2012), journals have proliferated, and there is a lower
proportion of NC-IUPHAR subcommittee coverage within
newer areas. These combined factors have made quality
judgments more difficult. This challenge is now compounded
(and thrusted into the foreground) by the “reproducibility
crisis” affecting the experimental biosciences in general and
rising rates of translational failure for pharmacology in
particular.9 Major concerns began surfacing in 2010 with a
report indicating that mislabeled or misidentified cell lines had
affected thousands of papers.10 This was followed in 2011 by the
company Bayer declaring that their in-house experimental
findings failed to match up with 65% of published target
Figure 3.GtoPdb entry for FAAH (GtoPdb Target ID (TID) 1440) with inhibitors mapped to it from the database release 2018.1. The record for PF-
04457845 is expanded to show the activity and references. Descriptions of the icons and rows are given in the GtoPdb Help documentation and FAQs.
Table 1. Statistics Associated with GtoPdb Relationship
Extractions
unique PubMed IDs linked to target−ligand pairs (C-P) 6466
unique PubMed IDs for primary D with quantitative “A-R” 6078
primary D with quantitative A-R, where C has a CID 5246
references linked to our substance identifiers (SIDs) in PubChem 9253
average compounds-per-document for A-R 1.1
ACS Omega Perspective
DOI: 10.1021/acsomega.8b00884
ACS Omega 2018, 3, 8408−8420
8411
validation claims,11 and in 2013 by a study pointing out
dispensing errors in assays.12 By 2015, poor antibody specificity
was also coming under the spotlight.13 At about the same time,
concerns were being raised about the inappropriate use of
statistics and other aspects of experimental design, which
prompted revisions of the author guidelines for the Br. J.
Pharmacol.14 These cautionary tales were compounded by a
2017 report that 29% of over 8500 vendor drug compounds
failed purity quality control.15 As if all this was not enough
(while not directly an experimental reproducibility issue per se),
the increasingly documented shortcomings of rodent models for
human diseases (e.g., those most often used in our secondary
citations) are being blamed for unsustainable rates of transla-
tional failure across all therapeutic areas.16
So, what canGtoPdb do in the face of all this? The first thing is
to maintain curatorial vigilance and stringency, backed up by
both NC-IUPHAR subcommittee oversight and direct user
feedback. This is helped by NC-IUPHAR’s familiarity with the
global research teams working in these areas over many years.
They can thus provide quality judgments of both the literature
and our database records curated from it. An example of this is
the subcommittee that recommends criteria for the interaction
reported for an orphan receptor with new cognate ligand(s) and
continues to update confirmed pairings.17 Also, our database
team (past and present) are scientists who have published in
their own right and are also members of the International
Society for Biocuration.18
We have taken other strategic options that, while certainly not
eliminating the problems, go some way to ameliorating them.
One of these is that we now enter the curatorial cycle more often
via publications that give explicit support to primary
experimental reports (i.e., we increasingly initially pick up
ligands and/or targets via a secondary publication, meaning they
are supported by at least two papers). In the interests of
reproducibility, we also try to find at least partially overlapping
confirmations from independent teams. We also routinely
exploit the PubMed features of both similar articles and cited by
(Figure 2). This gives us a convenient “360° walk” of any
publication as an adjunct QC. The former should pick up
publications on the same target and the latter may provide
corroboration of that activity modulation approach. However,
perhaps the dominant factor is that we do not aim for total c2p
coverage. This means we can be highly selective for small-data
coverage of pharmacology.
Two specific examples illustrate the importance of our c2p
quality judgments. The first concerns article retractions where
there is evidence of research misconduct or error.19 As a cross-
check, we have recently selected the 5801 retracted entries in
PubMed and checked which sources had added the 226 linked
SIDs (although this seems a reassuringly low proportion of the
total PubMed linkage count of 260 754). Of these, 225 turned
out to be derived from the automated IBM pipeline for patent
extraction that also operates on PubMed abstract texts.
However, the 226th was our own entry for lysophosphatidylcho-
line (LID 2508). It turns out that this had been initially
associated with a deorphanization report suggesting GPR4
activation by lysophosphatidylcholine and sphingosylphosphor-
ylcholine (LID 4032) but which was later retracted.20 Rather
than simply breaking the link that would lead to a loss of
contextual information, we have explained the retraction in the
comment fields for both ligands. While such retractions will only
pick up a small proportion of irreproducible c2p, they have been
increasing due to enhanced detection methods, so we will
continue to regularly intersect our reference lists.
The second cautionary example is an exclusion judgment.
During the updating of dipeptidyl peptidase-4 (DPP4)
Figure 4.Distribution of papers curated for ligand interactions in GtoPdb (release 2018.1). Numbers of papers are shown on the horizontal axis. The
vertical axis of journal titles shows the top-20 journals from a total of 920.
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inhibitors (TID 1612), we picked up a reported low-potency
interaction between this enzyme as a successful diabetes target
and atorvastatin, recorded in several databases.21 The original
paper declares an IC50 of 175 μM and Ki of 58 μM for
atorvastatin against pig DPP4 in vitro. However, this exceeds our
usual inclusion threshold of∼10 μM(although not applied as an
absolute rule) by nearly an order of magnitude, even for off-
target cross-reactivity. By comparison, we had curated the
human DPP4 drug omarigliptin (LID 8402) with an IC50 of 1.6
nM andKi of 0.8 nM, and atorvastatin (LID 2949) as having an 8
nM IC50 against human hydroxymethylglutaryl-CoA reductase.
To be clear, we are not questioning the authenticity of the
atorvastatin versus DPP4 result from ref 21 and we do take other
primary ligand reports from this journal. Notwithstanding, we
not only remain unconvinced as to the in vivo pharmacological
relevance but also note the absence of any subsequent in vitro
confirmatory reports. While our own judgment was therefore to
exclude it, we noted that this interaction had been captured by
other sources. The first of these was in DrugBank,22 where the
interaction (although not classified as pharmacologically
significant) is included, with human DPP4 listed as one of the
targets of atorvastatin (DB01076) but without activity values.
This contrasts with ChEMBL23 in which the same paper was
extracted but the database record maps the atorvastatin IC50
against the correct pig enzyme (CHEMBL3813). The ChEMBL
entry was then transitively propagated to both BindingDB
(atorvastatin as BDB 22164) and PubChem BioAssay (as AID
313843).
3.1. Challenges Associated with D. The challenge of
document curation (D) is that of scale and selectivity.
Estimating the total extractable D-A-R-C-P from the entire
document corpus relevant to pharmacology, drug discovery, and
chemical biology is difficult, to say the least. However, one
commercial source of such mappings, Excelra (previously GVK
BIO), has declared 1.34 million compounds from 112 000
curated papers in 2016, thus recording an average of∼12Cʼs per
paper.24 We can also compare with public resources, such as
ChEMBL,23 where release 24 declares 1.25 million structures
extracted from just under 70 000 documents (including 62 205
PubMed IDs according to European PubMed Central (EPMC)
indexing). This gives an average of ∼18 Cʼs per paper in this
case. The figures from BindingDB25 (for papers not overlapping
with ChEMBL) are 3385 PubMed IDs and 43 397 compounds,
with a slightly lower average of ∼14 Cʼs per paper (Gilson,
personal communication).
Compared to these other sources, GtoPdb Cʼs per paper
average of 1:1 reflects our typical selection of a single lead from
each primary paper (Table 1). One way to monitor our
selectivity is by the distribution of journal papers we curate
associated with ligands (Figure 4).
The distribution is long-tailed (i.e., 43% are singleton
journals), but we can detect the splits between our empirical
classifications. Thus, J. Med. Chem. tops the list of primary
reports. As we have defined them above, secondary papers are
widely distributed with Br. J. Pharmacol. being a good example
(although it includes some primary reports). As expected,
tertiary reports are fewer since only a minority of lead
compounds from the primary and secondary papers make it
through to clinical publications such as N. Eng. J. Med. or Br. J.
Clin. Pharm.
Other negative trends we have become aware of (besides the
reproducibility crisis outlined above) include proliferation (i.e.,
c2p being spread over 920 journal layouts with which we must
individually grapple with for curation), “salami-slicing” (i.e., data
from essentially the same study being divided between smaller
publishable units), and “me-too” papers. These ostensibly
disclose new data but for low-potency compounds unlikely to
ever be optimized. Another disappointing aspect is the relatively
slow penetration of Gold Open Access (GOA) into the
medicinal chemistry literature. Advantages of GOA include
that full-text HTML facilitates faster and more accurate curation
(e.g., reducing formatting errors associated with pasting IUPAC
names out of PDFs). In addition, both PubMed Central (PMC)
and EPMC not only index full text for searching but also for
different types of automated entity indexing (e.g., gene names).
As a domain, pharmacology has done somewhat better in open
access (OA) statistics than medicinal chemistry. For example,
the Br. J. Pharmacol. achieved 77% PubMed Central (PMC) free
full-text conversion for their 2001 PubMed IDs over the last 5
years (i.e., with a 6-month embargo period). The recently
launched sister journal, Pharmacol. Res. Perspect., was conceived
as GOA from the outset and thus has a PMC full-house for its
356 PubMed entries.
3.2. Challenges Associated with A. We made an early
decision to not add assay details to our database records because
we defer to the papers that we select to describe A (for those
subsets of R that we also select). There were two main reasons
for this. First, we had neither the curatorial capacity to add
detailed assay descriptions nor (until the BioAssay Ontology
becomes widely adopted) would we have a classification for
them.26 Second, while we do add brief notes for unusual or new
types of assays, it is difficult to make short summaries that
experimentalists could use without missing essential details,
which means they would have to consult the paper anyway. In
addition, even in the papers, descriptions often turn out to be
incomplete (e.g., missing precise buffer conditions). We feel
journals could do more here to mandate reproducible
descriptions since guidelines have been made available for
many years. These include Standards for Reporting Enzyme
Data27 and Minimum Information about a Bioactive Entity.28
However, it has to be accepted that across the major target
classes (GPCRs and ion channels in particular), assays are
becoming more complex and thus making editorial oversight
more difficult.29
3.3. Challenges Associated with R. We curate R as a
standard activity modulation parameter, where IC50, EC50, Ki,
and Kd are in the majority. We typically report these as specified
by authors, but we normalize concentrations to nanomolars and
then log these to pAct. We do not always accept the primacy of
what is in the paper but will correct in our database records that
which we judge as clearly erroneous. In practice, such
corrections are rare since, if we find that the frequency of
probable mistakes in any paper is high (due to questionable
quality or lack of editorial stringency), it is not selected for
curation. What we occasionally do fix are obvious unit mix-ups
between micromolars and nanomolars. A more common issue is
the quoting of significant figures way beyond those appropriate
to the error ranges of the assay. An example is SID 103716988
from PubChem BioAssay (AID 566893) with a BACE1 IC50
value of 1.38995 μM. Since the error of such protease substrate
turnover assays typically exceeds 10%, we would have rounded
this to three significant figures (but we did not select this
particular paper).
We also come across activity units that we may not typically
include but will mention in a comments field. For example,
covalent enzyme inhibition can be expressed as K (inact) in a
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paper, but we will use the IC50 at fixed preincubation time.
30 If
bioactivity is only reported as percentage inhibition at fixed
concentrations, then we take the absence of dose response data
to indicate that the work is more of a preliminary investigation.
While we would not usually curate such paper, we make
exceptions for what we judge as significant pharmacology from
difficult assays. We also do not normally add reported error
ranges to database records. This is because of lack of
standardization in different authors’ statistical treatment of
variance ranges as well as often a lack of clarity as to whether the
variation for technical or biological replicates was being
measured. As part of our procedure, we inspect PubChem
BioAssay31 records (i.e., A-R) that may already be linked to C.
We suspect few authors perform this cross-check (or at least do
not mention it). Sometimes this indicates to us that their
compound (or a close analogue) is in fact more potent against a
target that was not cross-screened in their paper. In such cases,
we mention this in curators notes.
3.4. Challenges Associated with C. Since curating the C
in D-A-R-C-P is arguably the most critical link for c2p, we
employ a series of curatorial steps. First and foremost, we must
discern if the authors have unequivocally specified a defined
structure for C that is either novel (as defined by its absence in
GtoPdb or other databases) or already exists in some other
provenanced source. We call this process a structure-to-
structure mapping (s2s). Second, we resolve any names
(semantic, common, nonproprietary, code names, and syno-
nyms) against that structure. We term this name-to-structure
(n2s), which includes Google checking. We may also have to
resort to a third process of image-to-structure (i2s) if this is the
only explicit description of C in the paper. We note that these
processes are reciprocal and that users may need to perform
them in different searching contexts (e.g., “what name does this
structure search retrieve from GtoPdb” is essentially a structure-
to-name query). The standard specifications we use for chemical
curation are shown below.
We have previously outlined reasons why we have chosen
PubChem as our primary source of C.32 Our s2s process is thus
centered on mapping key structures in papers to Compound
Identifiers (CIDs) and we subsequently submit our own records
to PubChem as Substance Identifiers (SIDs). The GtoPdb
release 2018.1 thus includes 6969 CIDs we have resolved by
curation, but in 95 cases, we are the sole source. These are
usually associated with novel structures but, as discussed below,
some may be alternative representations of pre-existing
structures. So why are our CID s2s mostly successfully mapped?
The main reason is that PubChem has now expanded to 95
million CIDs from 598 sources, thereby (from the alternative
databases of comparative size) becoming the de facto global
chemistry and bioactivity hub of choice.33 Our largest source
type overlap within PubChem of 80% comes from patents,
reflecting the fact that most structures in drug discovery reports
have already surfaced in PubChem via automated patent
extraction.34
The spectrum of equivocality and even frank errors we
regularly encounter in resolving C during s2s operations is
frustratingly broad and some of them have been reviewed
elsewhere.35,36 This can be largely attributed to the reluctance of
journals to mandate the use of public database identifiers for
chemical structures. By this omission, they lag several decades
behind molecular biology and bioinformatics, where editors
have long insisted on accession numbers for protein and nucleic
acid sequences to be reciprocally linked to PubMed records
(although even here, no journal actually had complete
compliance when surveyed in 2006).37 Since PubChem has
had stable chemical identifiers for well over a decade, it is unclear
Figure 5. Six principal types of chemical representation or routes of interconversion encountered and/or used during the curation of structures from
papers. Most cheminformatic tool-kits can execute the interconversions indicated by the arrows and major chemistry databases will also precompute
links between them. However, the round-tripping may not be perfect. Note also that the InChIKey cannot be converted to a structure but has key
utilities, including as a look-up string in Google.
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why such journal requirements have not appeared. One
exception is Nat. Chem. Biol., where author-specified SID
structures are submitted by the journal. The current metrics are
7949 SIDs from 2444 papers (but some are on-hold pending
publication). We have cross-referenced 51 of these papers and
linked 81 ligands. As a primary source journal, it lies just outside
the top-20 in Figure 4, since this is less mainstream for
pharmacology. However, the pre-established s2s is valuable and
makes it usually straightforward to link up the other entities. As
our largest primary source of compound extractions, J. Med.
Chem. has moved some way toward s2s with the introduction in
2014 of author-specified SMILES strings as open CSV tables
(Figure 5).38 For example, during curation, we cross-checked
the BACE1 inhibitor clinical compound for Alzheimer’s disease,
verubecestat (LID 8699), against the data sheet in Figure 6.
The inclusion of SMILES and their associated bioactivities
expedites GtoPdb curation. In the absence of this, in most other
journals, we have to pull out IUPAC text and convert this to
SMILES, InChI string, and InChIKey using either the OPSIN40
or Chemicalize.org web tools.41 However, we find that names
used by authorsmay need editing to remove formatting quirks or
typographical errors. In the absence of IUPAC names (e.g.,
Markush enumerations for an SAR series), wemay have to resort
to i2s (as SMILES) with OSRA.42 Raw i2s outputs from this
often need correcting but usually have a close enough similarity
match from a PubChem search. For poor images, we resort to a
chemical sketcher that outputs SMILES. We then search
PubChem via either SMILES, InChI string, InChIKey, SDF,
orMOL file (i.e., the standardized formats from Figure 5), where
we can usually resolve s2s via a CID exact match. We also cross-
check against what is in the paper to clarify the specification of
either enantiomeric mixtures and/or the resolved stereoisomer
forms as R/S and E/Z. Our last operation on the compound
entries is analogous to what we do for the papers in PubMed: a
360° walk of the structural neighborhood within PubChem.
This includes the precomputed relationships with similar
compounds (analogues), same connectivity (i.e., different
isomers or tautomers of the same skeleton), and mixtures,
which can have bioactivity data that may not be recorded for
parent compounds. In terms of deciding correctness (including
isomerism), our empirical judgment is if many PubChem
submitters agree on the structure (i.e., for a clear majority of
substances merged in the CID) and the names in multiple
sources also match, minimum parsimony would indicate both
s2s and n2s be correct.
Pharmacologically active peptides as C entities present
different s2s and n2s problems to small molecules. They require
options of representation as three-letter code or FASTA
sequence strings. Endogenous, unmodified peptides specifically
cleaved from precursors are usually specified in the UniProtKB
feature lines. Many are also specified as SMILES in PubChem
CIDs. Complications arise from author-declared names that
may not be IUPAC standard and/or include post-translational
modifications, such as N-acetylation or C-amidation. Exoge-
nous, synthetic peptides have the same issues and, moreover, are
often not found in sequence databases. Radioactively labeled
analogues (for small molecules as well as peptides) also feature
prominently in the pharmacological literature. However,
sometimes the molecular position of the label is unspecified,
so we must duplicate the structure record to point to distinct
references where data are generated with the labeled compound.
One negative aspect that has not changed in the last decade is
that approximately 40% of all declared drug development
candidates (i.e., where basic pharmacology and therapeutic
indications are partially outlined on company portfolio websites
and press releases) still have no associated structure (Lloyd,
personal communication). The unappreciated numerical scale
of the problem is reflected in the total of 7855 small-molecule
drug projects declared globally in 2017.43 Thus, the 40% would
represent over 3000 blinded compounds. What makes matters
Figure 6. Supplementary data from ref 39 with verubecestat as “compound 3”.
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worse is that many of these have entered their clinical phases,
even up to and beyond phase II, without explicit n2s in the
literature (so we make the judgment not to capture these in
GtoPdb). It is likely most of these structures are already in
PubChem, having been extracted from patents, but these C
entries do not specify which are the full leads or development
candidates (and the patents claiming the structure series are
often filed before these were chosen). This problem was
highlighted in 2012 in the context of stalled industry clinical
candidates offered as repurposing proposals, but where n2s
could not be found for many of the code numbers.44 This
pernicious and pervasive practice of c2p “blinding” (practiced by
academic drug discovery operations as well as commercial ones)
is based on the fear of competitive fast-following. Notwithstand-
ing, such blinding remains the single biggest obstacle to
capturing recent development compounds (i.e., by definition,
the cream of the pharmacological crop). It should be noted that
there is no statistical evidence that has established that delaying
open publication (or not publishing at all) reduces commercial
risk. One possible hope for amelioration is the growing pressure
on companies to increase the completeness and transparency of
clinical trial data.45
3.5. Challenges Associated with P. The use of stand-
ardized names and accession numbers to enable the resolution
of P is more common than for C entities in papers. Nevertheless,
ambiguity can still be a problem. In GtoPdb, we cross-refer
commonly used protein or gene identifiers, including our own
NC-IUPHAR nomenclature. For many reasons, we use the
UniProtKB accession number as an unequivocal, species-
specific, primary identifier, which, for human proteins, is the
Swiss-Prot curated entry. We also cross-refer the approved
HGNC gene symbol as part of our HGNC/NC-IUPHAR
collaboration. For those more familiar with NCBI annotation, a
RefSeq NM or NP can also be used, but a gene ID is preferable.
Where the paper specifies a protein complex, we need to resolve
this to the constituent subunit IDs. Notwithstanding our efforts
to resolve sequence identifiers, we are aware that in vitro activity
studies are often done with forms of the protein target, where
either the primary sequences are not identical to the Swiss-Prot
canonical entry or various kinds of post-translational mod-
ifications have been introduced that could plausibly affect
activity. For example, the protein could have a mutation used in
a resistance screen, have a His tag left over from purification,
Methionines may have been substituted to reduce oxidation
sensitivity, the N-glycosylation could be variable according to
the expression system, or, as in the cases of some proteases, both
the signal and propeptide may be omitted from the expression
construct. Here again, if notable deviations from wild-type are
specified by authors, these are mentioned in curators’ notes and
the reference is linked to the entry for further details.
4. ILLUSTRATION OF CURRENT c2p CHALLENGES
We can translate the general c2p challenges above into a specific
example different to the BIA 10-2474. In this case, we selected
“AZD9668: pharmacological characterization of a novel oral
inhibitor of neutrophil elastase” as the primary citation D46 for
the lead compound alvelestat (LID 6476). Our c2p authenticity
judgment was high for the following reasons: (a) the journal is
the fifth-ranking for our citations, (b) the authors are from an
established medicinal chemistry team in a major pharmaceutical
company, (c) it is open access (OA), (d) as an older paper, the
pharmacology has been corroboratively reproduced in other
articles as well as AstraZeneca published patents, and (e) the
level of detail in the paper allowed unequivocal D-A-R-C-P
assignments. For example, A-R was covered by the quote
“AZD9668 had a high binding affinity for human NE (Kd = 9.5
nM) and potently inhibited NE activity” (Table 1 from PMID
21791628). The calculated pIC50 (IC50) and Ki values for
AZD9668 for human NE were 7.9 (12 nM) and 9.4 nM,
respectively”. In addition, Table 2 (from PMID 21791628)
includes a log-transformed standard error of the mean as a pIC50
of 7.9 ± 0.12. For P, “neutrophil elastase” can be resolved to
UniProtKB accession P08246 and can also be identified as
HGNC symbol ELANE, NCBI gene ID 1991, and GtoPdb TID
2358. However, we noted, as for other enzyme families with a
history of alternative names, ELANE can potentially be confused
with five members of the chymotrypsin-like elastase family
(CELA1, CELA2A, CELA2B, CELA3A, and CELA3B). This
includes what used to be called pancreatic elastase that now
splits into the last three gene names in the list.
The assignment of n2s in this case had caveats that illustrate
an important c2p issue.
The information in the paper was consistent with the
proposed INN: list 104 WHO drug information, Vol. 24, No.
4, 2010, where alvelestat was first declared as n2s, as shown in
Figure 7.
Importantly, OPSIN converted the IUPAC name into
SMILES and InChIs that in turn allowed an unequivocal s2s
match with CID 46861623. During curation, we also noted that
this CID has clear submitter “majority vote” at 45 SIDs, thus
supporting the parsimonious assumption that this n2s (i.e., for
AZD9668 and the alvelestat INN) is correct. As a cross-check,
using the highest stringency query of “alvelestat”[Completesy-
nonym] in PubChem compound search (as a complete string
match) returns only CID 46861623. However, a simple name
search (that includes partial string matches) returned a
surprising result (Figure 8).
The INN name query returns four distinct CIDs (each
differing by molecular weight and InChIKey), which, from the
PubChem chemistry rules, must have at least one submitter each
with different n2s. Inspection shows that seven submitters for
CID 172650821 chose the tosylate salt with the correct parent
structure (albeit with two spellings of the counterion). It is
unclear where this mixture originated, since this is not an official
USAN salt name. However, we can establish that ChemIDplus
was the first to assign it in 2013 against a patent extraction by
Figure 7. Image for alvelestat from the INN proposal document. This
included the IUPAC name: N-{[5-(methanesulfonyl)pyridin-2-yl]-
methyl}-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-[3-
(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide.
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Thomson from 2010. Notwithstanding, it is neither clear how
the three SIDs for CID 71587812 (ChemIDplus, DrugBank, and
EPA DSSTox) omitted the trifluoride nor how the five
submitters for CID 75731913 (including four vendors) dropped
a methyl group. Statistics on the frequency of this type of n2s
error in open sources (i.e., not just stereochemistry ambiguities)
are difficult to come by. However, surveys of nonsystematic
identifiers (such as INNs) matching more than one structure
indicated a within-databases median of 2.5%, levels that, while
not catastrophic, are still confounding for c2p.47
4.1. D-A-R-C-P Limitations. Although we find D-A-R-C-P
mapping a useful summary of our curation process, we are aware
of its limitations. The most important of these is the incomplete
capacity (in terms of edge cases) to capture the full range of
mechanistic nuances of c2p. We can exemplify some of these
limitations as follows:
(1) There are many examples of pharmacologically significant
compounds with system perturbation read-outs but where
the mmoa has not yet been elucidated (i.e., C may have a
phenotypic A without a P). While lithium remains the
classic case (LID 5212), we can also use the example of
CCG-1423 (LID 6761). This inhibits RhoA transcrip-
tional signaling via an unknown target but is a useful tool
compound for disrupting this pathway in cancer.
(2) The conversion of prodrugs to drugs is a well-established
medicinal chemistry strategy but presents a curatorial
dilemma. In some cases, we can record inhibitory activity
for what is named as the approved drug in regulatory
documentation (i.e., C has an INN), but the metabolite is
more active by orders of magnitude (i.e., a “C-to-C”
conversion relationship). Our entry for ACE (TID 1613)
has 32 ligands including 13 prodrug/drug (lil/lat) pairs.
There are other cases that, while not designed as prodrugs
per se, generate active metabolites. Here, we provide
cross-pointers, as for the two hydroxyatorvastatins from
our atorvastatin entry (LID 2949).
(3) Some important medicines are molecularly undefined
substances and thus difficult to consistently map to
database identifiers (i.e., “C” is not pure). In the classic
case of heparin, we use a work around in the form of a
defined structure (LID 4214) to represent the use of
heterogeneous purified heparins in vivo. As a compro-
mise, this allows us to add a useful “C-A-P” mapping.
(4) Indirect mechanisms (i.e., where P is not the primary
efficacy target). Heparin is also a good example in this
case, where “C-P” is antithrombin III, but it indirectly acts
as a thrombin inhibitor (although such cases are rare).
(5) Imaging reagents. By definition, these are not therapeutic
but are very important diagnostically. We can often find a
reported “A-R-P” result but not always. Flortaucipir
binding to tau is an example (LID 9100).
(6) Single-target mapping has an obvious shortcoming where
evidence supports the binding of C is to a constitutive
heteromeric protein complex (i.e., consisting of one A-R
to multiple Pʼs). While NC-IUPHAR has defined a set of
complex targets for GtoPdb, there are exceptions where,
based on reported data, we assign a single protein from the
complex as the main binding partner. An example here is
presenilin (PSEN1, TID 2402) against which nine γ
secretase inhibitors are mapped. We made this choice to
constrain our relationship matrix, which would otherwise
be complicated with the additional four proteins in the γ
secretase complex.
(7) The other equally obvious shortcoming of single-target
mapping is broadly termed polypharmacology. This (as
one C against multiple A-R-P) can be divided into
multiple efficacy-related targets and off-targets as liability-
associated. Here again we veer toward stringency of only
including quantitatively defined (multiple binding)
targets and designating a data-supported primary efficacy
target. The drug verubecestat (LID 8699) is an interesting
example where we record that it is more potent against the
Figure 8. CIDs retrieved from PubChem with the term “alvelestat”. The SID counts for each of these in descending order are 3, 5, 45, and 7.
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paralogue BACE2 than its primary target in Alzheimer’s
disease of BACE1.
(8) Different physical forms of chemically identical active
compounds. These are very important therapeutically
(e.g., different crystallization polymorphs giving fast or
slow release), but we do not index formulations.
(9) New therapeutic modalities are on the horizon that will
present data model challenges. We already have recently
approved nucleic acid drug entries (i.e., where A and P are
missing) as exemplified by Nusinersen (LID 9416). We
also expect to see small molecules optimized for direct
binding against defined nucleic RNA sequences where we
will have to replace P with a defined RNA accession
number.48 Another area of development is large
molecule−small-molecule covalent conjugates (hybrids),
which are antibodies with cytotoxic payloads. Some are
already approved, such as ado-trastuzumab (LID 6928),
where, pending future options, we cross-point to the
“warhead” as a separate entity. This type of problem has
inspired global efforts directed toward the technicalities of
database registration of complex biological reagents in
general, including for regulatory requirements (e.g., the
idea of macromolecular InChIs is being developed).
5. FUTURE OUTLOOK
5.1. Overcoming Challenges. After focusing primarily on
challenges, we can move on to consider opportunities for c2p
enhancements, in the sense of at least overcoming some of the
challenges. However, we need to prelude this with an obvious
question; has our task of D-A-R-C-P curation become any easier
over the last 15 years? Stepping back to take our own perspective
we would have to answernot that much. Those easing effects
that we have noted include the following: (1) We make a
concerted effort to pass on curatorial problem-solving
experience internally through changes of team personnel. This
takes many forms but has an extent of formalization in our own
FAQ, our team publications, extensive support from NC-
IUPHAR committees, and the development of a sophisticated
curation tool that encodes accumulated guidelines for filling in
new database entries (i.e., we get better at what we do). (2)
Since the completion of the human genome and the annotation
efforts of resources such as HGNC and UniProt, protein target
ambiguity from author descriptions has diminished (but by no
means disappeared). Improved journal editorial guidelines have
also helped. (3) The three tools mentioned above, OPSIN,
Chemicalize, and OSRA, all appearing relatively recently, have
proved very useful. (4) The expansion of PubChem (via the
curated sources contributing to it, including our own) now
provides a 95 million chemical structure substrate for cross-
checking C from papers and patents.
5.2. Emerging Opportunities for Connecting c2p. The
most significant of these would be large-scale, open disinterring
of A-R-C-L-P relationships from pharmacology literature.
However, there seems no immediate prospect of these five
entities and attributes being surfaced and connected to the level
of precision that GtoPdb is known for. We should also point out
that, in general, selecting papers has not been rate limiting for
GtoPdb expansion, but curator time certainly is. So, while
GtoPdb will remain small and stringent as a strategic choice, it
does raise the question of just how large the c2p corpus could be,
with the crucial caveat of quality filtration if possible. As the
figures above show, ChEMBL has the largest manual extraction
capacity of any public source. However, even with these
resources, the combination of curatorial lead time and long
release cycles gives a backlog of up to 2 years. With GtoPdb’s
smaller in-house curation team, new lead compounds and
targets can be added within our 2 month release cycle.
Consideration of extraction scale leads naturally to the subject
of text mining and its more advanced form as natural language
processing. This has now developed to the point where it is
certainly capable of recognizing and extracting D, A, R, C, and P
from full text.49 However, joining them up as D-A-R-C-P
automatically is still challenging. In this context, it should be
noted that professional biocurators can make such joins from a
clearly laid out manuscript in amatter of minutes (but somewhat
longer if the entities are confusingly arranged, including
Markush-only structures, or results are partitioned into multiple
supplementary data files). However, even as progress is being
made in the precision of automated entity extraction from text,
the position regarding publishers permissioning for text mining
of the 4.3 million full text articles in PubMed Central and EPMC
(recently expanded by ∼2 million via the “unpaywall” initiative)
remains unclear. This presents a paradox in that, since patents
are free of licensing restrictions, SureChEMBL not only
generates an open database of 19.2 million chemical structures
automatically extracted from documents but also performs an
extended bioentity mark-up within selected documents.50
So what future developments could drive the availability of D-
A-R-C-P? We suggest, logically, a process needs to be widely
adopted whereby authors specify both the entities and the key
data relationships from their own papers. Since they carried out
the scientific work, they are de facto the best stakeholder group
to do this. There are three corollaries. First, iteration between
authors and journals and biocurators would be necessary to
formalize the output (including some level of ontology
mapping), and second, collaboration with open databases is
necessary to accept the input. Arguably, there is no fundamental
technical impediment to something along these lines being
introduced, so resistance to this seems more of a social problem.
So why has progress toward this been slow and what could
accelerate it? There aremany possible factors of which only a few
salient ones can be considered here. The first to mention is that
from a journal pilot study in 2008 for protein interactions,
authors proved unenthusiastic about filling in even a relatively
simple data sheet.51 Thus, if even just “P-to-P” data seemed
onerous to comply with, then full D-A-R-C-P mark-up would
seem to present an even greater adoption barrier (especially
where C could expand out to dozens of structures from SAR
sets). Nonetheless, we have seen some progress in this direction,
including our own experience of working with Br. J. Pharmacol.
and Br. J. Clin. Pharm. to update guidelines for authors on
reporting c2p. They are now required to provide GtoPdb
identifiers and nomenclature for the targets and ligands which
their article is about.More recently, we have introduced a system
whereby novel key entities (i.e., not already in GtoPdb) are
communicated to the team for consideration before publication.
Consequently, those within our remit are added and the new
identifiers provided.
Journals have a fundamental role to play in c2p by providing
clear guidance to authors on the database identifiers and
submission formats to use. This also ideally extends to
supporting live-links to external database entries from within
articles to help readers to find further information and context
for the C and Pʼs as described. However, the four journals
mentioned above constitute a relatively small proportion of the
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total coverage for GtoPdb and, beyond these, there are neither
declarations nor even word on the grapevine suggesting that
many more journals (e.g., from our Figure 4 list) are planning to
formally introduce author mark-up of D-A-R-C-P. A com-
parative paradox here is that authors complying with sequence
accession numbers as a condition of publication (as mentioned
above) have now reached a submission rate of ∼3500 per day.
Nonetheless, there are simple steps authors can take, even when
there is no specific journal mandate. As we have shown,
providing public database identifiers for C and P is a basic
requirement, and if C is novel, then providing structural
information in a standard format recognized by open chemistry
tools is crucial. Authors and journals will see the benefits of
enhanced connectivity within the whole knowledge domain,
increasing impact, and, ultimately, citations.
To conclude, while this perspective has focused on GtoPdb, it
covers key points regarding the curatorial conversion of
unstructured, or semistructured c2p data into structured
database records. These can not only justifiably be termed
“knowledge bases” but are also being merged into “big data”
aggregations for data mining, including artificial intelligence
approaches. The prospective advantages for the pharmacology,
chemical biology, and drug discovery fields are thus huge.
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K.; Vasic-́Rac ̌ki, Đ.; Carrea, G.; Magnusson, A.; Schmid, A.;
Wohlgemuth, R.; et al. Guidelines for Reporting of Biocatalytic
Reactions. Trends Biotechnol. 2010, 28, 171−180.
(28) Orchard, S.; Al-Lazikani, B.; Bryant, S.; Clark, D.; Calder, E.; Dix,
I.; Engkvist, O.; Forster, M.; Gaulton, A.; Gilson, M.; et al. Minimum
Information about a Bioactive Entity (MIABE). Nat. Rev. Drug
Discovery 2011, 10, 661−669.
(29) Lane, J. R.; May, L. T.; Parton, R. G.; Sexton, P. M.;
Christopoulos, A. A Kinetic View of GPCR Allostery and Biased
Agonism. Nat. Chem. Biol. 2017, 13, 929−937.
(30) Krippendorff, B.-F.; Neuhaus, R.; Lienau, P.; Reichel, A.;
Huisinga, W. Mechanism-Based Inhibition: Deriving KIand and kInact
Directly from Time-Dependent IC50 Values. J. Biomol. Screening 2009,
14, 913−923.
(31) Wang, Y.; Cheng, T.; Bryant, S. H. PubChem BioAssay: A
Decade’s Development toward Open High-Throughput Screening
Data Sharing. SLAS Discovery 2017, 22, 655−666.
(32) Southan, C.; Sharman, J. L.; Benson, H. E.; Faccenda, E.; Pawson,
A. J.; Alexander, S. P. H.; Buneman, O. P.; Davenport, A. P.;McGrath, J.
C.; Peters, J. A.; et al. The IUPHAR/BPS Guide to PHARMACOL-
OGY in 2016: Towards Curated Quantitative Interactions between
1300 Protein Targets and 6000 Ligands. Nucleic Acids Res. 2016, 44,
D1054−D1068.
(33) Southan, C. Caveat Usor: Assessing Differences between Major
Chemistry Databases. ChemMedChem 2018, 13, 470−481.
(34) Southan, C. Expanding Opportunities for Mining Bioactive
Chemistry from Patents. Drug Discovery Today Technol. 2015, 14, 3−9.
(35) Clark, A. M.; Williams, A. J.; Ekins, S. Machines First, Humans
Second: On the Importance of Algorithmic Interpretation of Open
Chemistry Data. J. Cheminf. 2015, 7, 9.
(36) Hersey, A.; Chambers, J.; Bellis, L.; Bento, A. P.; Gaulton, A.;
Overington, J. P. Chemical Databases: Curation or Integration by User-
Defined Equivalence? Drug Discovery Today Technol. 2015, 14, 17−24.
(37) Noor, M. A. F.; Zimmerman, K. J.; Teeter, K. C. Data Sharing:
How Much Doesn’t Get Submitted to GenBank? PLoS Biol. 2006, 4,
No. e228.
(38) Gilson, M. K.; Georg, G.; Wang, S. Digital Chemistry in the
Journal of Medicinal Chemistry. J. Med. Chem. 2014, 57, 1137.
(39) Scott, J. D.; Li, S. W.; Brunskill, A. P. J.; Chen, X.; Cox, K.;
Cumming, J. N.; Forman, M.; Gilbert, E. J.; Hodgson, R. A.; Hyde, L.
A.; et al. Discovery of the 3-Imino-1,2,4-Thiadiazinane 1,1-Dioxide
Derivative Verubecestat (MK-8931)−A β-Site Amyloid Precursor
Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s
Disease. J. Med. Chem. 2016, 59, 10435−10450.
(40) Lowe, D. M.; Corbett, P. T.; Murray-Rust, P.; Glen, R. C.
Chemical Name to Structure: OPSIN, an Open Source Solution. J.
Chem. Inf. Model. 2011, 51, 739−753.
(41) Southan, C.; Stracz, A. Extracting and Connecting Chemical
Structures from Text Sources Using Chemicalize.Org. J. Cheminf. 2013,
5, 20.
(42) Filippov, I. V.; Nicklaus, M. C. Optical Structure Recognition
Software To Recover Chemical Information: OSRA, An Open Source
Solution. J. Chem. Inf. Model. 2009, 49, 740−743.
(43) Lloyd, I. Pharma Projects Pharma R&D Annual Review; Citeline,
2018.
(44) Southan, C.; Williams, A. J.; Ekins, S. Challenges and
Recommendations for Obtaining Chemical Structures of Industry-
Provided Repurposing Candidates. Drug Discovery Today 2013, 18,
58−70.
(45) Goldacre, B.; Lane, S.; Mahtani, K. R.; Heneghan, C.; Onakpoya,
I.; Bushfield, I.; Smeeth, L. Pharmaceutical Companies’ Policies on
Access to Trial Data, Results, and Methods: Audit Study. BMJ 2017,
358, j3334.
(46) Stevens, T.; Ekholm, K.; Granse, M.; Lindahl, M.; Kozma, V.;
Jungar, C.; Ottosson, T.; Falk-Hakansson, H.; Churg, A.; Wright, J. L.;
et al. AZD9668: Pharmacological Characterization of a Novel Oral
Inhibitor of Neutrophil Elastase. J. Pharmacol. Exp. Ther. 2011, 339,
313−320.
(47) Akhondi, S. A.; Muresan, S.; Williams, A. J.; Kors, J. A. Ambiguity
of Non-Systematic Chemical Identifiers within and between Small-
Molecule Databases. J. Cheminf. 2015, 7, 54.
(48) Rizvi, N. F.; Howe, J. A.; Nahvi, A.; Klein, D. J.; Fischmann, T.O.;
Kim, H.-Y.; McCoy, M. A.; Walker, S. S.; Hruza, A.; Richards, M. P.;
et al. Discovery of Selective RNA-Binding Small Molecules by Affinity-
Selection Mass Spectrometry. ACS Chem. Biol. 2018, 13, 820−831.
(49) Krallinger, M.; Rabal, O.; Lourenco̧, A.; Oyarzabal, J.; Valencia,
A. Information Retrieval and Text Mining Technologies for Chemistry.
Chem. Rev. 2017, 117, 7673−7761.
(50) Papadatos, G.; Davies, M.; Dedman, N.; Chambers, J.; Gaulton,
A.; Siddle, J.; Koks, R.; Irvine, S. A.; Pettersson, J.; Goncharoff, N.; et al.
SureChEMBL: A Large-Scale, Chemically Annotated Patent Docu-
ment Database. Nucleic Acids Res. 2016, 44, D1220−D1228.
(51) Orchard, S.; Hermjakob, H. Shared Resources, Shared Costs
Leveraging Biocuration Resources. Database 2015, 2015, No. bav009.
ACS Omega Perspective
DOI: 10.1021/acsomega.8b00884
ACS Omega 2018, 3, 8408−8420
8420
